ABSTRACT
Objective: To determine frequency and prognosis of stroke in patients with hyperglycemia in the acute phase at the Neurology department of Yalgado Ouedraogo Teaching University Hospital. Patients and methods: We conducted a 6 years cross-sectional study on acute stroke patients admitted in the neurology department of Yalgado Ouedraogo Teaching Hospital from 1st January 2011 to 30 June 2017. This study included only patients with hyperglycemia at admission (≥ 6.1 mmol/l). Results: The overall frequency of admission hyperglycemia was 7.27% with respectively 8 % in AIS and 6.1% in ICH. The overall mean age of patients with was 58.83 years. The majority of patients was male gender (52.6%). According to diabetes status, 70.8% of patients were known diabetics (39.4%), 31.4% new diabetics and 29.2% had stress hyperglycemia. The frequency of known diabetics was higher in AIS (p=0.000003) while stress hyperglycemia was most frequent in ICH (p= 0.0001). The majority of patients (74.5 %) had severe neurological deficit with NIHSS ˃15. Severe hyperglycemia (≥ 11.0 mmol/l) was present in 62.7% of patients. The majority of patients was treated with insulin (52.6 %) who was given alone mostly in AIS (p˂0.05). Patients who did not received any treatment were in the group of ICH (p˂0.05). The overall mean length of stay was 13.35 days. At discharge, 60.6% of patients were euglycemics. The overall mortality was 22.6% with higher mortality in ICH (p˂0.05). At discharge, the majority of survivors (69.3%) had worse functional outcome (mRS˃2). The factors influencing the mortality of AIS were known diabetes, severe hyperglycemia and no hypoglycemic agents (p˂0.05). In ICH, the mortality risk factors were previous diabetes, glucose level (7-7.7 mmol/l) and t combined hypoglycemic agents. Conclusion: Admission hyperglycemia in stroke is rare in our context. Stress hyperglycemia is most common in ICH. Insulin treatment was mostly used. Mortality rate of higher both in AIS and ICH.

ABSTRACT
COVID-19 which is caused by SARS-CoV-2 is among the severe respiratory disease to be witnessed to date. SARS-Cov-2 brought about therapeutic and preventive difficulties all over the globe. The aim of this review is to evaluate the best possible therapeutic options to tackle the Novel Coronavirus related disease. We extracted relevant published studies with keywords such as COVID-19 therapies, Sars-Cov-2 treatment and Noval Coronavirus antiviral therapy from Pubmed and carefully studied them. We focused on Tocilizumab, chloroquine and hydroxychloroquine, Lopinavir/Ritonavir, Remdesivir, Traditional Chinese Medicine and Ivermectin. Coronavirus induce Cytokines Releasing Syndrome (CRS) which in turn causes Cytokines Storm. This is the inflammatory response which causes the releasing of large number of IL-6. This causes increased vascular permeability which in turn result in the infiltration of fluids in the alveolar spaces and causes breathing problems. Tocilizumab can block the inflammatory response induced by SARS-CoV-2 infection and hence prevent the vascular permeability which in turn prevents the pulmonary edema and Disseminated Intravascular Coagulation (DIC) and hence prevent respiratory failure. Remdesivir which is an adenosine nucleotide analogue, has broad-spectrum antiviral activity against RNA Viruses. This means remdesivir can prevent the viral replication and hence lower the viral load and ultimately reduce the duration of illness and hospitalization. Ivermectin which is FDA approved broad spectrum antiparasitic agent, works by preventing the entrance of viral protein in the host cell nucleus. Ivermectin binds to the viral protein transporters Importin (IMP) α and β1. This action prevents the binding of the viral protein to the Importin (IMP) which results in the lower infection rate and decreased viral load. Lower rate of infection and decreased viral load will reduce duration of illness and prevent transmission of SARS-CoV-2. So, the concomitant .......

ABSTRACT
Anorectal Traumas (ART) are rare injuries in children. Therefore, reports from developing countries are also rare. Their etiologies are variable. We present a case of penetrating anterior extraperitoneal rectal trauma with transanal approach was used to access, and primarily repair, full-thickness rectal lacerations. The female patient was successfully managed without a colostomy and without complications. Her anal function was almost perfectly preserved.